For the Inventor, By the Inventor

Enter assignee name

Waltham, MA, United States of America

Genome Therapeutics Corporation

USPTO Granted Patents = 19

% Expired Patents = 5.3

Forward Citations = 896

Loading Chart...

Loading Chart...

32 inventors (with patents filed for the assignee):

David E Bush (8 out of 68 patents)

Lynn Doucette-Stamm (4 out of 59 patents)

Randall D Little (4 out of 13 patents)

4. Gary L Breton (4 out of 5 patents)

5. Jen-i Mao (3 out of 6 patents)

6. Jason Samuel Simon (2 out of 15 patents)

7. Tim Keith (2 out of 9 patents)

8. Paul Van Eerdewegh (2 out of 9 patents)

9. Kristina Allen (2 out of 12 patents)

10. Sunil D Pandit (2 out of 9 patents)

11. Craig Deloughery (2 out of 3 patents)

12. Keith G Weinstock (2 out of 3 patents)

13. John P Carulli (2 out of 4 patents)

14. Robert R Recker (2 out of 9 patents)

15. Mark L Johnson (2 out of 6 patents)

19 patents: Sort by Forward Citations

1. 7285400 - High bone mass gene of 11q13.3 (2007-10-23),

2. 7041814 - [object Object] (2006-05-09),

3. 6800744 - Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics (2004-10-05),

4. 6780609 - High bone mass gene of 1.1q13.3 (2004-08-24),

5. 6747137 - Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics (2004-06-08),

6. 6737519 - Human genes relating to respiratory diseases and obesity (2004-05-18),

7. 6699703 - Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics (2004-03-02),

8. 6683165 - Human gene relating to respiratory diseases and obesity (2004-01-27),

9. 6673910 - Nucleic acid and amino acid sequences relating to M. catarrhalis for diagnostics and therapeutics (2004-01-06),

10. 6610836 - Nucleic acid amino acid sequences relating to Klebsiella pneumoniae for diagnostics and therapeutics (2003-08-26),

11. 6605709 - Nucleic acid and amino acid sequences relating to Proteus mirabilis for diagnostics and therapeutics (2003-08-12),

12. 6583275 - Nucleic acid sequences and expression system relating to Enterococcus faecium for diagnostics and therapeutics (2003-06-24),

13. 6583266 - Nucleic acid and amino acid sequences relating to mycobacterium tuberculosis and leprae for diagnostics and therapeutics (2003-06-24),

14. 6562958 - Nucleic acid and amino acid sequences relating to Acinetobacter baumannii for diagnostics and therapeutics (2003-05-13),

15. 6551795 - Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics (2003-04-22),

Company Overview

Genome Therapeutics Corporation is a biotechnology company based in Waltham, MA, specializing in the development of innovative gene therapies. The organization focuses on harnessing advanced genomic technologies to address genetic disorders and improve patient outcomes. With a commitment to research and development, Genome Therapeutics is engaged in pioneering work that encompasses gene editing, gene delivery systems, and therapeutic applications aimed at transforming the landscape of genetic medicine.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

19 Patents

#78 in Waltham, MA

#1,049 in Massachusetts

#17,138 in US

#32,663 in the World

Waltham, MA, United States of America

Genome Therapeutics Corporation

Forward Citations = 896

32 inventors:

David E Bush (8 out of 68 patents)

Lynn Doucette-Stamm (4 out of 59 patents)

Randall D Little (4 out of 13 patents)

4. Gary L Breton (4 out of 5 patents)

5. Jen-i Mao (3 out of 6 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Genome Therapeutics Corporation. Retrieved from https://idiyas.com/company/genome-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…